Partner Aaron Tantleff was quoted on the recent milestones in the U.S.-EU Privacy Shield data transfer agreement, which has been facing criticism and questioning over whether it could stand up to a legal challenge. In The Wall Street Journal’s Morning Risk Report article, “Hope Fading for Privacy Shield Agreement,” Tantleff was quoted saying, “While there was great support for the passage of Privacy Shield, given the impact it has on some of the largest global economies, the reality is that the ability for Privacy Shield to pass legal scrutiny in the current climate is all but impossible.”
Tantleff also shared his insights with SC Magazine and was quoted in the article, “European Data Protection Supervisor Calls Privacy Shield Ineffective,” on June 1, 2016. Tantleff said that because data is global and virtual and becoming more difficult to localize, the Privacy Shield is critical. He said, “Facing the growing uncertainty of the model contract clauses, organizations need a stable, valid method to transfer the data of EU citizens across the Atlantic.”
Tantleff also shared his insights with SC Magazine and was quoted in the article, “European Data Protection Supervisor Calls Privacy Shield Ineffective,” on June 1, 2016. Tantleff said that because data is global and virtual and becoming more difficult to localize, the Privacy Shield is critical. He said, “Facing the growing uncertainty of the model contract clauses, organizations need a stable, valid method to transfer the data of EU citizens across the Atlantic.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”